Miranda MBA - Entera Bio CEO Director
| ENTX Stock | USD 1.59 0.03 1.85% |
Insider
Miranda MBA is CEO Director of Entera Bio
| Age | 47 |
| Address | Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002 |
| Phone | 972 2 532 7151 |
| Web | https://www.enterabio.com |
Entera Bio Management Efficiency
The company has return on total asset (ROA) of (0.7061) % which means that it has lost $0.7061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4467) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio's management efficiency ratios could be used to measure how well Entera Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.79 in 2024. Return On Capital Employed is likely to drop to -0.87 in 2024. At this time, Entera Bio's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 209 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christian Mueller | Immutep Ltd ADR | N/A | |
| Kathryn Andrews | Alterity Therapeutics | 57 | |
| BBus CA | Alterity Therapeutics | 63 | |
| David MD | Alterity Therapeutics | 63 | |
| Robert Cherny | Alterity Therapeutics | N/A | |
| BSc BSc | Alterity Therapeutics | 69 | |
| Chad MBA | NLS Pharmaceutics AG | N/A | |
| Steven Targum | Alterity Therapeutics | N/A | |
| iur LLM | NLS Pharmaceutics AG | 58 | |
| Sharon Keys | NLS Pharmaceutics AG | N/A | |
| Maurice Zauderer | Vaccinex | 78 | |
| MBA CFA | Vaccinex | 50 | |
| Rudolph Tanzi | Alterity Therapeutics | 66 | |
| Shengfei Fang | Immutep Ltd ADR | N/A | |
| Elizabeth Evans | Vaccinex | 51 | |
Management Performance
| Return On Equity | -1.45 | ||||
| Return On Asset | -0.71 |
Entera Bio Leadership Team
Elected by the shareholders, the Entera Bio's board of directors comprises two types of representatives: Entera Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Entera. The board's role is to monitor Entera Bio's management team and ensure that shareholders' interests are well served. Entera Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Entera Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hillel MBA, Chief Officer | ||
| Miranda MBA, CEO Director | ||
| II MD, Chief Officer | ||
| Gregory Burshtein, Chief Development | ||
| Dana CPA, Chief Officer |
Entera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Entera Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.45 | ||||
| Return On Asset | -0.71 | ||||
| Operating Margin | (71.93) % | ||||
| Current Valuation | 50.48 M | ||||
| Shares Outstanding | 36.83 M | ||||
| Shares Owned By Insiders | 19.01 % | ||||
| Shares Owned By Institutions | 14.45 % | ||||
| Number Of Shares Shorted | 44.15 K | ||||
| Price To Earning | 2.10 X | ||||
| Price To Book | 8.85 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.